Evan Friedman - Concepedia

Author

Evan Friedman

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

E FRIEDMAN, E. Friedman, Evan Friedman, Evan J. Friedman, Sharon Wilczynski

Publications

697

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Western University Rutgers Cancer Institute

About

Evan Friedman is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	229
2	Natural Sciences	1	1	43
3	Biochemistry	1	1	43
4	Clinical Nutrition	1	1	54
5	Hepatology	1	1	44

Evan Friedman

Publications

599

Citations

H-Index

Page 1

	Year	Citations
A Study to Determine the Effects of Food and Multiple Dosing on the Pharmacokinetics of Vorinostat Given Orally to Patients with Advanced Cancer Eric H. Rubin, Nancy Agrawal, Evan Friedman, Clinical Cancer Research	2006	113
Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial Dirk Schürmann, Deanne Jackson Rudd, Saijuan Zhang, The Lancet HIV Phase 1BPharmacologyAntiviral Drug DevelopmentAntiviral TherapyVirology	2020	88
Lack of a Significant Drug Interaction between Raltegravir and Tenofovir Larissa Wenning, Evan Friedman, James Kost, Antimicrobial Agents and Chemotherapy	2008	72
Effect of Low-, Moderate-, and High-Fat Meals on Raltegravir Pharmacokinetics Diana M. Brainard, Evan Friedman, Bo Jin, The Journal of Clinical Pharmacology ObesityNutritionMedicineClinical NutritionMedical Nutrition Therapy	2010	54
A Single Supratherapeutic Dose of Vorinostat Does Not Prolong the QTc Interval in Patients with Advanced Cancer Pamela N. Münster, Eric H. Rubin, Simon Van Belle, Clinical Cancer Research	2009	48
Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics Marian Iwamoto, William D. Hanley, Amelia S. Petry, Antimicrobial Agents and Chemotherapy PharmacotherapyAntiviral DrugAntiviral Drug DevelopmentResistance Mutation (Virology)Chronic Kidney Disease	2009	44
Effect of Different Durations of Ketoconazole Dosing on the Single‐Dose Pharmacokinetics of Midazolam: Shortening the Paradigm S. Aubrey Stoch, Evan Friedman, A. Maes, The Journal of Clinical Pharmacology Medicinal ChemistryCytochrome P450 3APharmacological StudyBiochemistryDifferent Durations	2009	43
Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV Randolph P. Matthews, Wendy Ankrom, Evan Friedman, Clinical and Translational Science	2021	42
Effect of Different Durations and Formulations of Diltiazem on the Single-Dose Pharmacokinetics of Midazolam: How Long Do We Go? Evan Friedman, Iain P. Fraser, Yinghong Wang, The Journal of Clinical Pharmacology	2011	32
Performance Evaluation of EEG/EMG Fusion Methods for Motion Classification Jacob Tryon, Evan Friedman, Ana Luisa Trejos	2019	28

Page 1